LDC graduation deferred to 2029: what it means for pharmaceutical patents

Bangladesh was due to graduate from least-developed-country status on 24 November 2026. At the end of October 2026 the United Nations granted a three-year deferral, and graduation is now set for November 2029. This briefing replaces our October note, which was written while the original date still stood.

For the pharmaceutical sector the date matters more than for any other. The TRIPS transition arrangement for least-developed countries is what has allowed Bangladeshi manufacturers to produce patented medicines without licence, and it lasts only while the country remains an LDC.

What the deferral changes

The transition exempts least-developed countries from granting and enforcing pharmaceutical product patents. It runs until 1 January 2033 or until a country ceases to be an LDC, whichever comes first. With graduation moved to November 2029, Bangladesh keeps that flexibility for three more years than the industry had been planning for.

The Patent Act 2023 reflects the same position: medicine and agrochemical product patents are not granted while the transition lasts. That exclusion now continues until graduation.

What it does not change

• The direction of travel. When the transition ends, ordinary TRIPS obligations apply: product patents become enforceable, and manufacturing a patented medicine without authority becomes infringement. The deferral moves the date, not the destination.
• The need for a product-by-product analysis. Exposure depends on which molecules are under patent in Bangladesh, which are off-patent globally and which are already covered by licences. That is an application-by-application question.
• The treatment of applications filed before graduation, which remains a live question for every applicant in the queue.
• The licensing conversation. Originators and manufacturers who had opened discussions against a 2026 deadline now have room to conclude them properly instead of abandoning them.

What to do with the time

1. 01Run a freedom-to-operate analysis across the product portfolio against patents actually granted and in force in Bangladesh — not against the global patent position, which is a different and usually broader picture.
2. 02Identify the products where the exposure is real and material, and separate them from the ones where it is theoretical.
3. 03Continue or open licensing discussions where a licence is the commercial answer. Negotiating after graduation, with infringement exposure already running, is a materially worse position.
4. 04For originators: review the Bangladeshi filing position for the portfolio and decide which rights are worth pursuing and on what terms, including filings that can be made now and examined later.
5. 05For both: watch the registration pipeline, and watch for any further change to the graduation timetable.

The end of the transition will still be the largest single change to the intellectual property position of an industry in Bangladesh in a generation. The deferral has turned a deadline measured in weeks into one measured in years, and the companies that use the time will be in a different position in 2029 from those that wait for it.